+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Phenotype frequency of human leukocyte antigens in Japanese patients with renal cell carcinoma who responded to interferon-alpha treatment



Phenotype frequency of human leukocyte antigens in Japanese patients with renal cell carcinoma who responded to interferon-alpha treatment



International Journal of Urology 3(6): 435-440



Because of the high cost, low overall response rate (10% to 20%), and poor quality of life during interferon therapy for advanced renal cell carcinoma, it is important to distinguish patients likely to respond to treatment. The expression of human leukocyte antigens (HLA) may serve as a clinical marker for response to interferon treatment in patients with renal cell carcinoma. We compared HLA phenotype frequency in 37 Japanese patients with advanced renal cell carcinoma who showed a favorable response to interferon-alpha, in 93 similar patients, before treatment, who did not receive interferon-alpha, and in 939 healthy Japanese volunteers (historical control data). Six HLA antigens, B35, Bw48, Bw60, DRw6, DRw8, and DR9, were expressed at a significantly lower rate in the 93 pretreatment patients with renal cell carcinoma, compared with the control subjects. Three HLA antigens, excluding Bw60, DRw6, and DRw8, were expressed at a significantly higher rate in the patients who responded to interferon-alpha, compared with the pretreatment patients with renal cell carcinoma and control subjects. Three HLA antigens, B35, Bw48, and DR9, were expressed at a significantly higher rate in patients with renal cell carcinoma who showed a sensitivity to interferon-alpha, and could be important markers for clinical response to this antitumor therapy.

(PDF emailed within 1 workday: $29.90)

Accession: 046973654

Download citation: RISBibTeXText

PMID: 9170569


Related references

The treatment of renal cell carcinoma with human leukocyte alpha-interferon. Journal of Urology 130(6): 1063-1066, 1983

Treatment of metastatic renal cell carcinoma with native human leukocyte alpha interferon. Murphy, G P And S Khoury (Ed ) Progress in Clinical And Biological Research, Vol 303 Therapeutic Progress in Urological Cancers; International Symposium, Paris, France, June 29-July 1, 1988 Xxx+913p Alan R Liss, Inc : New York, New York, Usa Illus 862, 1989

Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial. Cancer Treatment Reports 69(3): 263-267, 1985

Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma. International Journal of Urology 15(9): 794-799, 2008

Treatment of patients with metastatic renal cell carcinoma results of two clinical phase ii studies with alpha 2 interferon versus alpha 2 interferon plus vinblastine or gamma interferon in 55 patients. Journal of Urology 137(4 PART 2): 329A, 1987

The treatment of renal cell carcinoma with recombinant human leukocyte interferon. Hinyokika Kiyo. Acta Urologica Japonica 31(3): 377-386, 1985

Alpha(human leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial. Journal of Biological Response Modifiers 2(4): 343-347, 1983

Further enhancement of natural killer (NK) activities and interferon (IFN)-gamma production by recombinant human interleukin-12 (rhIL-12) in the patients with renal cell carcinoma (RCC) during the treatment with IFN-alpha compared with before the treatment. Journal of Clinical Oncology 26(15_suppl): 16068-16068, 2016

Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. Investigational New Drugs 30(3): 1046-1054, 2012

Interferon-alpha and interferon-gamma in advanced renal cell carcinoma: Treatment results, survival, and prognostic factors in 81 patients. Onkologie 20(6): 466-471, 1997

Autologous tumor vaccine combined with sequential interferon gamma and interferon alpha in the treatment of patients with metastatic renal cell carcinoma. Proceedings of the American Association for Cancer Research Annual Meeting 36(0): 224, 1995

Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urologic Oncology 27(6): 598-603, 2008

Immunologic phenotype of lymphocytes and ultrastructure of leucocytes in the blood of patients with metastatic renal cell carcinoma treated with recombinant interferon alpha-2B and 5-fluorouracil. Eksperimental'naya Onkologiya 20(1): 53-59, March, 1998

Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie. Cancer 95(11): 2324-2330, 2002

Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma: Less efficacy compared with intravenous interleukin-2 and interferon alpha: Results of a multicenter phase II trial from the Groupe Francais d'lmmunotherapie. Cancer 95(11): 2324-2330, December 1, 2002